A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 2511-2511 ◽  
Author(s):  
Carlos Alberto Gomez-Roca ◽  
Valentina Boni ◽  
Victor Moreno ◽  
John Charles Morris ◽  
Jean-Pierre Delord ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

scholarly journals First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors

2019 ◽  
Vol 145 (7) ◽  
pp. 1798-1808 ◽  
Author(s):  
Ignacio Garrido-Laguna ◽  
Ian Krop ◽  
Howard A. Burris ◽  
Erika Hamilton ◽  
Fadi Braiteh ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

472 A phase I study of IMGN388, an antibody drug conjugate targeting av integrin, in patients with solid tumors

2010 ◽  
Vol 8 (7) ◽  
pp. 152 ◽  
Author(s):  
J. Bendell ◽  
K. Moore ◽  
A. Qin ◽  
D. Johnson ◽  
J. Schindler ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document